Using Integrative Data Analysis to Examine the Impact of Psychosocial Treatments for Black Cocaine Users Enrolled in the NIDA Drug Abuse Treatment Clinical Trials Network (CTN)

使用综合数据分析来检验心理社会治疗对参加 NIDA 药物滥用治疗临床试验网络 (CTN) 的黑色可卡因使用者的影响

• 批准号: 10450340
• 负责人: Keith N. Humphreys
• 金额: $ 9.8万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-15 至 2022-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10450340
• 关键词: Behavioral; Buprenorphine; California; Caring; Clinical Treatment; Clinical Trials; Clinical Trials Network; Clinics and Hospitals; Cluster randomized trial; Cocaine Users; Collaborations; Data Analyses; Data Science; Disease; Drug Use Disorder; Drug abuse; Drug usage; Drug user; Electronic Health Record; Enrollment; Future; Goals; Health; Health Sciences; Health system; Healthcare; Hybrids; Hydromorphone; Infrastructure; Intervention; Managed Care; Medicaid; Methadone; Mirtazapine; National Institute of Drug Abuse; Oral; Oregon; Pharmaceutical Preparations; Pharmacotherapy; Placebos; Primary Health Care; Protocols documentation; Randomized; Recovery; Research; Research Personnel; Resources; San Francisco; Services; Supervision; Telephone; Testing; Training; Trillium; Universities; Veterans; Vulnerable Populations; addiction; effectiveness implementation study; effectiveness implementation trial; experience; implementation trial; improved; mHealth; methamphetamine use; novel; opioid use disorder; peer; peer support; phase III trial; prescription opioid; programs; psychosocial; success; trial comparing

Abstract The Western States Node’s (WSN) research agenda for the National Drug Abuse Treatment Clinical Trials Network (CTN) competing renewal tests interventions to fill gaps in the Addiction Care Cascade, where progressively fewer people with drug use engage in treatment, receive pharmacotherapy, are retained in care, and experience sustained recovery. The Node proposes to continue the successful partnership between Oregon Health & Science University (OHSU; Todd Korthuis, MPI) and University of California San Francisco (UCSF; James Sorensen, Co-I), and adds Stanford University/Palo Alto VA (Keith Humphreys, MPI) to the collaboration. Six diverse health systems participate in WSN: 1) OCHIN, 2) The Palo Alto VA and national Veterans Healthcare Administration, 3) The OHSU health system, 4) Stanford Hospital and Clinics, 5) ProtoCall Services, Inc., and 6) Health Share and Trillium Medicaid managed care organizations. The WSN tests novel interventions that expand access to medications for opioid use disorder (MOUD). The overarching goal of the WSN’s competing renewal application is to conduct collaborative research within the CTN that fills gaps in the Addiction Care Cascade and thereby enhances the lives of people living with drug use disorders. Our Addiction Care Cascade-focused research agenda developed through conversations with diverse investigators and stakeholders including people who use drugs. Two research themes (medication trials and hybrid implementation trials to close gaps in the Addiction Care Cascade) provide four examples of CTN studies that could help close treatment gaps. In Research Theme 1 (medication trials), Medication Trial 1 targets people with OUD who are not interested in currently available MOUD and randomizes them to receive long acting oral hydromorphone versus facilitated referral methadone or buprenorphine to improve engagement and retention in treatment. Medication Trial 2 is a multisite phase 3 trial of mirtazapine versus placebo for people with methamphetamine use disorder to reduce methamphetamine use. In Research Theme 2 (hybrid implementation trials), two trials compare strategies to enhance engagement and retention on MOUD. Hybrid Effectiveness-Implementation Trial 1 is a cluster- randomized trial of telephonic + mHealth behavioral support services to improve retention on buprenorphine in primary care. Hybrid Effectiveness-Implementation Trial 2 tests a telementoring peer support intervention versus weekly peer supervision to improve peer success in engaging and retaining people who use drugs in treatment. We suffuse this research agenda with the Node’s infrastructure and expertise in vulnerable populations, health systems, electronic health records research, data science and clinical trials management. WSN offers these resources to the CTN network for use in future CTN protocols. Finally, WSN continues to use the CTN as a platform for training, dissemination, and research applications.

抽象的 西方国家节点（WSN）的研究议程，用于国家药物滥用治疗临床试验 网络（CTN）竞争续签测试干预措施，以填补成瘾护理级联的空白， 吸毒的人越来越少地从事治疗，接受药物治疗，保留在护理中， 并经验持续康复。节点提议继续在 俄勒冈州健康与科学大学（OHSU； Todd Korthuis，MPI）和加利福尼亚大学旧金山分校 （UCSF； James Sorensen，Co-I），并增加了斯坦福大学/帕洛阿尔托·弗吉尼亚州（Keith Humphreys，MPI） 合作。参与WSN的六种不同的卫生系统：1）Ochin，2）Palo Alto VA和National 退伍军人医疗保健管理局，3）OHSU卫生系统，4）斯坦福医院和诊所，5） ProtoCall Services，Inc。和6）健康共享和医疗补助托管护理组织。 WSN 测试新的干预措施，以扩大对阿片类药物使用障碍药物的访问（MOUD）。 WSN竞争性续签应用的总体目标是在内部进行合作研究 填补成瘾护理级联缺口的CTN，从而改善了与之相处的人们的生活 药物使用障碍。我们的成瘾护理通过对话制定了以级联级联的研究议程 包括使用毒品的人在内的各种研究人员和利益相关者。两个研究主题 （药物试验和混合实施试验，以弥合成瘾护理级联的差距）提供了四个 CTN研究的示例，可以帮助缩小治疗差距。在研究主题1（药物试验）中， 药物试验1针对OUD的人，他们对当前可用的Moud和 随机将其随机接收长期表演的口服液压电话与准备的推荐方法或 丁丙诺啡可改善治疗中的参与度和保留率。药物试验2是一个多站点3 甲基苯丙胺使用障碍患者的米氮平与安慰剂的试验以减少 甲基苯丙胺的使用。在研究主题2（混合实施试验）中，两个试验将策略与 增强对MOUD的参与和保留。杂交有效性实施试验1是一个群集 - 电话 + MHealth行为支持服务的随机试验，以改善对丁丙诺啡的保留 初级保健。混合有效性 - 实现试验2测试远程测试对等支持干预措施 与每周的同伴监督，以提高同伴在参与和保留使用毒品的人方面的成功 治疗。我们以节点的基础架构和脆弱的专业知识来使这一研究议程充满 人群，卫生系统，电子健康记录研究，数据科学和临床试验管理。 WSN向CTN网络提供这些资源，以在将来的CTN协议中使用。最后，WSN继续 使用CTN作为培训，传播和研究应用程序的平台。